Application of STAT3 inhibitor in enhancing killing power of NK cells against tumor cells
A tumor cell and NK cell technology, applied in the field of immunity, can solve the problems of no report on the killing ability of NK cells to tumor cells, no report on the use of LobocrassinSTAT3 inhibitor, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0024] 1. Experimental materials
[0025] RPMI-1640 and fetal bovine serum (FBS) were purchased from GIBCO; NK cell culture medium was purchased from CellGro, Germany.
[0026] Recombinant human interleukin 2 (rhIL-2) was purchased from Shuanglu Pharmaceutical; lymphocyte separation liquid was purchased from NycomedPharma.
[0027] Human gastric cancer cells SGC-7901 and BCG-823 were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences.
[0028] 2. Experimental method
[0029] 1. Mononuclear cell isolation, grouping and NK cell culture
[0030] Peripheral blood from healthy volunteers was collected and subjected to Ficoll density gradient centrifugation to separate peripheral blood mononuclear cells (PBMC). On Day 0, use NK cell culture medium containing 5% autologous plasma and 80 U / ml gentamycin to adjust the PBMC to the initial cell number of 1.0×10 6 / L, divide the cells into the control group and the treatment group, the control group is routinely ...
Embodiment 2
[0056] A STAT3 inhibitor, containing Lobocrassin C or Lobocrassin D, also contains a pharmaceutically acceptable carrier or excipient, made into a pharmaceutically acceptable dosage form; the pharmaceutically acceptable carrier or excipient includes one or more A solid, semi-solid or liquid excipient, and pharmaceutically acceptable dosage forms include tablets, capsules, granules, injections, pills, syrups, powders, and ointments.
Embodiment 3
[0058] A pharmaceutical preparation for enhancing the lethality of NK cells on tumor cells, which contains Lobocrassin C or Lobocrassin D, and also contains pharmaceutically acceptable carriers or excipients, made into pharmaceutically acceptable dosage forms; pharmaceutically acceptable Carriers or excipients include one or more solid, semi-solid or liquid excipients, and pharmaceutically acceptable dosage forms include tablets, capsules, granules, injections, pills, syrups, powders, and ointments. The tumor cells are preferably gastric cancer.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More